Vitestro has closed a $70 million Series B financing round, oversubscribed, to accelerate the commercial and regulatory readiness of its autonomous robotic blood collection platform. The Dutch medical robotics company attracted a strong mix of strategic and financial backers for the round.
New strategic investors include U.S. healthcare organisations Labcorp Venture Fund, Mayo Clinic, and Sutter Health. They are joined by new financial investors InterVest, MGFO, PGGM, Puma Venture Capital, and ROM Utrecht. Existing investors Invest-NL, supported by InvestEU, EIC Fund, Fred Moll, NYBC Ventures, and Sonder Capital all continued their support.
Diagnostic blood collection is the highest-volume invasive medical procedure performed worldwide, with billions of procedures carried out every year. Yet it remains heavily dependent on skilled human staff, prone to variability, and a persistent source of operational pressure for hospitals and outpatient clinics.
Vitestro is building technology to change that. Its Aletta® Autonomous Robotic Phlebotomy Device, known as the ARPD, combines multimodal imaging, advanced robotics, and artificial intelligence to locate suitable veins, guide needle insertion, and collect blood samples with high precision. The system is designed to support phlebotomy departments by handling routine draws, reducing human-dependent variability, and improving consistency for patients across high-volume clinical settings.
"Diagnostic blood collection remains the highest-volume invasive medical procedure globally, with billions of procedures performed annually," said Toon Overbeeke, CEO and co-founder of Vitestro. "Our technology has evolved from a novel vision into a clinically validated reality, and we are grateful for the support of this distinguished syndicate of strategic, healthcare, and life science investors as we move toward broad clinical adoption."
The Series B proceeds will be directed toward advancing the next generation of the Aletta® ARPD, with a focus on deepening its integration into high-volume clinical workflows. Vitestro will also use the capital to scale manufacturing, expand its clinical program, and build out the commercial infrastructure needed to support broader adoption.
A significant portion of the funding supports Vitestro's U.S. FDA De Novo regulatory pathway. The company is working toward commercial launch beginning in Europe, with the U.S. market as the next major milestone. Hiring is also planned to meet demand from healthcare providers engaging with the platform.
Vitestro is headquartered in the Netherlands and was founded with a focus on engineering, robotics, AI, and clinical commercialisation. The Aletta® ARPD holds CE marking, making it the world's first and only certified autonomous robotic phlebotomy device of its kind. It is currently being deployed in clinical and pre-commercial settings across Europe.
The company brings together expertise across medical robotics, imaging systems, and AI to address what it describes as a large and underserved clinical need. Aletta® does not simply assist phlebotomists. It is built to perform the procedure autonomously, end to end.
The FDA De Novo pathway is the regulatory route Vitestro is pursuing for U.S. clearance. This pathway is typically used for novel medical device types that have no legally marketed predicate, which reflects the genuinely new category Vitestro has created.
The backing from major U.S. health systems signals more than financial confidence. Mayo Clinic, Sutter Health, and Labcorp Venture Fund bring direct insight into the clinical environments where Vitestro's technology would operate at scale.
"The Labcorp Venture Fund sees strong potential in solutions that modernize core diagnostic processes and improve consistency for patients," said Megann Vaughn Watters, Head of Labcorp Venture Fund. "Applying robotics, multimodal imaging and AI to clinically validated diagnostic blood collection is an exciting approach, and we're thrilled to support Vitestro as they advance this important work."
The round also drew a notable endorsement from Fred Moll, one of the most recognised figures in surgical robotics. Moll co-founded Intuitive Surgical, the company behind the da Vinci system, and later founded Auris Health. He is now a partner at Sonder Capital, an existing Vitestro investor.
"Vitestro is redefining one of the largest and most under innovated clinical workflows with a first-of-its-kind autonomous robotic platform for diagnostic blood collection addressing an enormous unmet global market need," Moll said. "I believe this technology has the potential to establish a new standard of care, much as robotic surgery did in its early days."
